Pharmaceuticals

Rising Neurological Disorders Fueling The Growth Of The Due To Aging Population And Increasing Motor Impairments Is Contributing To Changes In The MSI-H And dMMR Market

May 1, 2026May 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

From Its 2026 Market Size, What Value Is The MSI-H And dMMR Market Projected To Reach By 2030?

The market size for msi-h and dmmr has seen substantial growth in recent years. It is projected to expand from $7.57 billion in 2025 to $9.32 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 23.1%. The increase observed in the past can be credited to the discovery of msi-h and dmmr biomarkers, the initial success of immune checkpoint inhibitors, the escalating incidence of colorectal and endometrial cancer, the broadening scope of molecular diagnostics, and regulatory approvals for therapies based on biomarkers.

The msi-h and dmmr market size is anticipated to experience substantial growth in the coming years. It is projected to reach $21.13 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 22.7%. This expansion during the forecast period is fueled by factors such as the increasing adoption of precision oncology, the growing application of genomic testing in cancer care, the broadening of immunotherapy indications, rising investments in biomarker research, and the accumulation of clinical evidence supporting tumor-agnostic approaches. Prominent trends within this period are expected to include the heightened use of immunotherapy for msi-h and dmmr tumors, increased reliance on companion diagnostics for patient stratification, an elevated focus on tumor-agnostic cancer treatments, the proliferation of combination immunotherapy regimens, and enhanced awareness of biomarker-driven oncology.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24324&type=smp

Which Primary Drivers Are Impacting The MSI-H And dMMR Market Growth?

The MSI-H and dMMR market is expected to experience growth due to the increasing prevalence of cancer. Cancer is a group of diseases defined by the uncontrolled multiplication and spread of abnormal cells within the body. This escalation in cancer cases is primarily linked to aging populations, as the risk of developing cancer significantly rises with age, owing to the cumulative impact of genetic mutations and prolonged exposure to various risk factors over time. In cancer treatment, MSI-H and dMMR are utilized to identify tumors that exhibit high mutation rates due to deficiencies in DNA repair mechanisms. These biomarkers are crucial for guiding immunotherapy decisions, given that such tumors often respond better to immune checkpoint inhibitors, and they also provide insights into patient prognosis and potential genetic syndromes. For example, in January 2024, the American Cancer Society, a US-based non-profit organization, indicated that in 2023, the United States was estimated to have 1,958,310 new cancer cases and 609,820 cancer-related deaths. These figures are projected to climb in 2024, with approximately 2,001,140 new cancer cases and 611,720 deaths anticipated, thereby highlighting a continuous rise in cancer incidence and mortality. Hence, the growing prevalence of cancer is a key driver for the expansion of the MSI-H and dMMR market.

What Segment Categories Shape The MSI-H And dMMR Market Segment Landscape?

The msi-h and dmmr market covered in this report is segmented –

1) By Treatment Type: Immune Checkpoint Inhibitors (ICIs), Combination Therapy

2) By Indication: Endometrial, Gastric, Colorectal Cancer, Small Intestine Cancer, Cervical Cancer, Other Indications

3) By Stage: Early Stages, Advanced Stages

4) By End User: Hospitals, Oncology Clinics, Research Institutions, Homecare

Subsegments:

1) By Immune Checkpoint Inhibitors (ICIs): Programmed Cell Death Protein 1 Inhibitors, Programmed Cell Death Ligand 1 Inhibitors, Cytotoxic T-Lymphocyte Antigen 4 Inhibitors

2) By Combination Therapy: Immune Checkpoint Inhibitor + Chemotherapy, Immune Checkpoint Inhibitor + Targeted Therapy, Immune Checkpoint Inhibitor + Radiation Therapy, Immune Checkpoint Inhibitor + Other Immunotherapies

Which Trends Are Influencing Demand In The MSI-H And dMMR Market?

Leading companies in the MSI-H and dMMR market are concentrating on developing innovative treatments, such as combination therapy, to boost treatment effectiveness and improve patient outcomes. Combination therapy for MSI-H and dMMR cancers involves utilizing two or more treatment methods, frequently immunotherapy agents like checkpoint inhibitors, or integrating immunotherapy with chemotherapy, targeted therapy, or radiation. This strategy aims to enhance treatment response, overcome resistance, and extend survival for patients with tumors that exhibit high microsatellite instability or deficient mismatch repair. For instance, in April 2025, Bristol-Myers Squibb Company, a US-based pharmaceutical firm, secured United States Food and Drug Administration (FDA) approval for the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) as a first-line therapy for metastatic colorectal cancer (mCRC) with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) features, thereby advancing treatment options for this challenging cancer subtype. This approval signifies a major milestone in the management of MSI-H and dMMR cancers, as it introduces an effective new therapeutic choice that targets multiple pathways to enhance patient survival and response rates, addressing unmet medical needs in this patient population.

Who Are The Companies Operating Across The MSI-H And dMMR Market Value Chain?

Major companies operating in the msi-h and dmmr market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis International AG, AstraZeneca PLC, Bristol-Myers Squibb Company, GSK plc., Takeda Pharmaceutical Company, Incyte Corporation, Exact Sciences Corp., BeiGene LTD., Summit Therapeutics Inc., Tempus Labs Inc., Guardant Health, NeoGenomics Laboratories Inc., Promega Corporation, Caris Life Sciences, and Owkin.

Get The Full MSI-H And dMMR Market Report:

https://www.thebusinessresearchcompany.com/report/msi-h-and-dmmr-global-market-report

Which Region Accounts For The Largest Portion Of The MSI-H And dMMR Market?

North America was the largest region in the MSI-H and dMMR market in 2025. The regions covered in the msi-h and dmmr market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized MSI-H And dMMR Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/msi-h-and-dmmr-global-market-report

Browse Through More Reports Similar to the Global MSI-H And dMMR Market 2026, By The Business Research Company

Automotive Human Machine Interface Hmi Market Report 2026

https://www.thebusinessresearchcompany.com/report/automotive-human-machine-interface-hmi-global-market-report

Electronic Data Interchange Edi Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/electronic-data-interchange-edi-software-global-market-report

Digital Aerospace Mro Market Report 2026

https://www.thebusinessresearchcompany.com/report/digital-aerospace-mro-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795